You are here: Industry Insights > drug

News List

Drug No Better Than Placebo for Lower Back, Leg Pain drugs.com
March 23, 2017
The widely prescribed pain drug pregabalin (brand name: Lyrica) may be no better than a placebo when it comes to treating the back and leg pain known as sciatica, a new clinical trial suggests.
Bellus Health agrees to sell Thallion to US firm Taro Pharmaceuticals pharmaceutical-technology
March 21, 2017
Bellus Health has signed an agreement to sell its wholly owned subsidiary Thallion Pharmaceuticals, including all the...
Cost of prescriptions to rise 20p in England pharmatimes
March 20, 2017
The prescription charge in England will rise next month by 20 pence to £8.60 for each medicine or appliance ...
BELLUS Health Sells Subsidiary Thallion Pharmaceuticals to Taro Pharmaceuticals americanpharmaceuticalreview
March 20, 2017
BELLUS Health Inc. has entered into a share purchase agreement with Taro Pharmaceuticals Inc. for the sale of BELLUS Health's wholly-owned subsidiary Thallion Pharmaceuticals Inc. including all the rights to the drug candidate ShigamabTM.
UK NICE Board approves changes to drug evaluation process pharmaceutical-technology
March 20, 2017
The UK National Institute for Health and Care Excellence (NICE) board has approved changes to the drug evaluation process.
NICE backs use of Biogen’s Zinbryta for MS pharmatimes
March 17, 2017
Eligible patients with multiple sclerosis should be able to get routine access to Biogen’s Zinbryta on the NHS in the next ...
Fantastic Returns on Rare Disease Drug Development en-cphi
March 17, 2017
The growing interest of the pharmaceutical industry in rare disease drugs has not showed any sign of wane.
Colorado unapproved drug and dietary supplement makers ordered to cease operations for federal viola cphi-online
March 16, 2017
Dietary supplement products "misbranded" and unapproved new drugs being marketed with drug claims despite not being approved for any use.
US nod for Novartis’ breast cancer drug Kisqali pharmatimes
March 15, 2017
Novartis’ selective cyclin-dependent kinase inhibitor Kisqali has been approved by the US Food and Drug Administration...
FDA grants orphan drug designation to Boehringer Ingelheim’s antibody BI 836858 pharmaceutical-technology
March 14, 2017
The US Food and Drug Administration (FDA) has granted orphan drug designation to Boehringer Ingelheim’s anti-CD33 ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 49 50 Next page